Hemostemix Inc. (CVE:HEM – Get Free Report) was up 57.1% during trading on Tuesday . The stock traded as high as C$0.12 and last traded at C$0.11. Approximately 516,088 shares traded hands during mid-day trading, an increase of 439% from the average daily volume of 95,821 shares. The stock had previously closed at C$0.07.
Hemostemix Stock Performance
The company has a market capitalization of C$9.15 million, a P/E ratio of -5.25 and a beta of 0.20. The company has a 50-day simple moving average of C$0.08 and a 200 day simple moving average of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Stocks Helping to Bring AI to Healthcare
- How Technical Indicators Can Help You Find Oversold StocksÂ
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- Election Stocks: How Elections Affect the Stock Market
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
